Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Update

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 105,800 shares, a decrease of 9.6% from the March 15th total of 117,100 shares. Based on an average daily trading volume, of 34,600 shares, the short-interest ratio is currently 3.1 days. Approximately 2.4% of the shares of the stock are short sold.

Aprea Therapeutics Price Performance

Shares of APRE stock opened at $5.70 on Wednesday. Aprea Therapeutics has a 1 year low of $2.78 and a 1 year high of $8.85. The stock’s 50 day simple moving average is $6.52 and its two-hundred day simple moving average is $5.21. The company has a market cap of $30.95 million, a PE ratio of -1.43 and a beta of 1.03.

Aprea Therapeutics (NASDAQ:APRE) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.36). The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.33 million. Equities research analysts expect that Aprea Therapeutics will post -2.38 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating and set a $20.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday, March 26th. Wedbush upped their price objective on Aprea Therapeutics from $9.00 to $11.00 and gave the company an “outperform” rating in a research report on Wednesday, March 27th.

Insider Activity at Aprea Therapeutics

In other news, Director Bernd R. Seizinger purchased 6,860 shares of the company’s stock in a transaction that occurred on Wednesday, March 13th. The stock was bought at an average cost of $7.29 per share, with a total value of $50,009.40. Following the completion of the purchase, the director now owns 33,685 shares in the company, valued at $245,563.65. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders bought 9,870 shares of company stock valued at $71,952. Insiders own 20.90% of the company’s stock.

Institutional Investors Weigh In On Aprea Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of APRE. Renaissance Technologies LLC raised its holdings in shares of Aprea Therapeutics by 5.7% in the first quarter. Renaissance Technologies LLC now owns 297,900 shares of the company’s stock worth $554,000 after buying an additional 15,977 shares during the period. Jane Street Group LLC purchased a new stake in shares of Aprea Therapeutics in the second quarter worth approximately $54,000. BNP Paribas Arbitrage SNC purchased a new stake in shares of Aprea Therapeutics in the third quarter worth approximately $40,000. Millennium Management LLC raised its holdings in shares of Aprea Therapeutics by 35.7% in the fourth quarter. Millennium Management LLC now owns 164,626 shares of the company’s stock worth $53,000 after buying an additional 43,293 shares during the period. Finally, Geode Capital Management LLC purchased a new stake in shares of Aprea Therapeutics in the second quarter worth approximately $74,000. 34.19% of the stock is currently owned by hedge funds and other institutional investors.

About Aprea Therapeutics

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors, ovarian, breast, and prostate cancers.